Last reviewed · How we verify

Muhammad Rahman Efendi Nasution — Portfolio Competitive Intelligence Brief

Muhammad Rahman Efendi Nasution pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Non Opioid Analgesics Non Opioid Analgesics phase 3 Non-opioid analgesic Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allodynic Therapeutics, Inc · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 shared drug class
  4. Nevakar, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Muhammad Rahman Efendi Nasution:

Cite this brief

Drug Landscape (2026). Muhammad Rahman Efendi Nasution — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/muhammad-rahman-efendi-nasution. Accessed 2026-05-17.

Related